Shots:
- PharmaShots speaks with Thomas Chalberg, Founder and CEO of Genascence Corporation, and Annahita Keravala, Founder and CSO of Genascence Corporation
- Thomas and Annahita speak eloquently about Genascence’s current lead program, GNSC-001, for osteoarthritis of the knee, and shed light on the unmet medical needs in the disease
- The duo highlighted the safety and tolerability profiles from the P-Ib trial evaluating GNSC-001 for osteoarthritis of the knee and shared key details about the initiation of the P-IIb/III trial next year
About the Authors:
Thomas Chalberg
A trailblazer in the fields of health and technology through the innovative use of molecular biology and advanced biologics, Tom Chalberg is a scientist, entrepreneur, and executive in Silicon Valley. Before founding Genascence, Tom was Founder and CEO of SightGlass Vision, Inc., which was acquired by a joint venture between CooperVision and EssilorLuxottica in 2021. Previously, Tom was Chief Operating Officer of Oncorus, Inc. (NASDAQ: ONCR); and Founder and CEO of Avalanche Biotechnologies (now Adverum Biotechnologies; NASDAQ: ADVM). He is a Partner at Polymerase Capital, and currently serves on the boards of iRenix Medical (executive chairman), Ethris GmbH, and Chameleon Biosciences.
Annahita Keravala
Innovative and passionate biotech professional with extensive experience in research and development of AAV-mediated gene therapies for prevalent as well as rare diseases. Enthusiastic about developing cutting-edge technologies using local or systemic delivery for debilitating disorders. Strong scientific background in AAV vector optimization- cassette engineering and capsid discovery, molecular biology, biochemistry, and stem cell biology. Proven ability to establish research infrastructure in biotech start-ups with a track record of strategic leadership and management of cross-functional teams to achieve corporate goals.
Related Post: CXO Talks: Tim O’Connell from Emtelligent in a Striking Conversation with PharmaShots
